Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931628 | 0.88 | NHERF1 (0.52) | POLBTP53NPC1RAB9ALMNA | |
| SCHEMBL23258734 | 0.85 | NHERF1 (0.55) | POLBTP53NPC1RAB9ALMNA | |
| SCHEMBL28081980 | 0.84 | TP53 (0.69) | POLBTP53NPC1RAB9ALMNA | |
| SCHEMBL23258395 | 0.83 | MEN1 (0.57) | POLBTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23258271 | 0.83 | MEN1 (0.65) | POLBTP53RAB9AMEN1KMT2A | |
| SCHEMBL28082015 | 0.83 | MAOA (0.59) | POLBTP53NPC1RAB9ALMNA | |
| SCHEMBL28081963 | 0.82 | NPC1 (0.60) | TP53NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28081990 | 0.81 | KDM4E (0.63) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL12501305 | 0.81 | HRH4 (0.58) | POLBTP53LMNAMEN1KMT2A | |
| SCHEMBL6245500 | 0.81 | KDM4E (0.57) | POLBLMNAMEN1KMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105820104-B | A kind of indoles -2- amides compound with anti-inflammatory effect and its application in preparing anti-inflammatory drugs | 温州医科大学 | 2018-12-11 | — | — | CN | disclosed |
| CN-105820104-A | Indole-2-acetamide compound with anti-inflammatory effect, and application thereof in preparation of anti-inflammatory drugs | 温州医科大学 | 2016-08-03 | — | — | CN | disclosed |
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | BAYER HEALTHCARE AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7045544-B2 | Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-05-16 | — | — | US | disclosed |
| EP-1578418-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004056768-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056768-A2 | USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003028719-A1 | SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | DCK, UROD, QDPR | POLB 4030/4885TP53 1697/4885NPC1 3391/4885 |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | ECE1, ECE2, EDNRA | POLB 3892/4885TP53 4414/4885NPC1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.